{"id":"W3042751537","doi":"10.1016/j.ahj.2020.07.008","title":"Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design","year":2020,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; Principia Biopharma; Sanofi Genzyme; Bausch Health; Intercept Pharmaceuticals; AstraZeneca; Amarin Corporation; Novo Nordisk; Asahi Group Holdings; Medicines Company; Intarcia Therapeutics; Regeneron Pharmaceuticals; Mylan; Ionis Pharmaceuticals; Boston Scientific Corporation; Abbott Vascular; Duke Clinical Research Institute; MannKind Corporation; European Commission; Kowa Company; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Semaglutide; Medicine; Overweight; Weight loss; Diabetes mellitus; Obesity; Adverse effect; Internal medicine; Population; Disease; Placebo; Type 2 diabetes; Intensive care medicine; Endocrinology; Liraglutide","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005859013,0.001766589,0.002317748,0.0007277431,0.0008599398,0.00122356,0.0009840825,0.001918018,0.0103723],"category_scores_gemma":[0.00420073,0.0006190644,0.001751077,0.0006264434,0.001399531,0.0007130186,0.0008079689,0.002224206,0.001970215],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006247888,"about_ca_system_score_gemma":0.002936306,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003569853,"about_ca_topic_score_gemma":0.0008643381,"domain_scores_codex":[0.9972787,0.001577036,0.0002111164,0.0003110924,0.0003540583,0.000267991],"domain_scores_gemma":[0.9984611,0.0003596751,0.0002483884,0.0001253856,0.0002382617,0.0005671175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.6409771,0.01838049,0.01614168,0.0170014,0.002210462,0.001117337,0.0004360296,0.001336254,0.02309605,0.01047958,0.02621714,0.2426063],"study_design_scores_gemma":[0.463944,0.3014266,0.0372374,0.00423447,0.007263574,0.001647299,0.0003309872,0.002513084,0.01067086,0.008884052,0.161638,0.0002096757],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.4326115,0.0713781,0.02316953,0.01203575,0.007461442,0.3670423,0.01345628,0.001154133,0.07169105],"genre_scores_gemma":[0.5071323,0.03157469,0.02847466,0.01357002,0.003199977,0.3931265,0.003431176,0.0001379916,0.01935265],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.0103723,"threshold_uncertainty_score":0.03469884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01636962010853827,"score_gpt":0.2445446049952341,"score_spread":0.2281749848866959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}